Thursday, November 26, 2020 10:53:09 PM
Recent CAPR News
- Form SC 13G - Statement of Beneficial Ownership by Certain Investors • Edgar (US Regulatory) • 11/12/2024 04:46:58 PM
- Capricor Therapeutics to Present Exosome Platform Updates at 2024 American Association of Extracellular Vesicles Annual Meeting • GlobeNewswire Inc. • 11/12/2024 02:00:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 11/12/2024 05:15:17 AM
- Capricor Therapeutics to Present Third Quarter 2024 Financial Results and Recent Corporate Update on November 13 • GlobeNewswire Inc. • 11/05/2024 02:00:00 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 10/22/2024 09:11:23 PM
- Capricor Therapeutics Announces Closing of Underwritten Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares • GlobeNewswire Inc. • 10/18/2024 08:01:00 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 10/17/2024 08:15:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/17/2024 10:01:22 AM
- Capricor Therapeutics Announces Pricing of Approximately $75 Million Public Offering of Common Stock • GlobeNewswire Inc. • 10/17/2024 10:00:00 AM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 10/16/2024 08:35:56 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/16/2024 08:25:24 PM
- Capricor Therapeutics Announces Proposed Public Offering of Common Stock • GlobeNewswire Inc. • 10/16/2024 08:17:48 PM
- Form S-3/A - Registration statement under Securities Act of 1933: [Amend] • Edgar (US Regulatory) • 10/16/2024 05:31:08 PM
- Capricor Therapeutics Announces Positive Long-Term Data from HOPE-2 OLE Study in Duchenne Muscular Dystrophy at 2024 World Muscle Society Congress • GlobeNewswire Inc. • 10/11/2024 01:15:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/09/2024 01:16:15 PM
- Capricor Therapeutics Announces Initiation of Rolling Submission of Biologics License Application (BLA) with U.S. FDA for Deramiocel for the Treatment of Duchenne Muscular Dystrophy • GlobeNewswire Inc. • 10/09/2024 01:15:00 PM
- Capricor Therapeutics to Present Long-Term Data from HOPE-2 Open Label Extension Study at 2024 World Muscle Society Congress • GlobeNewswire Inc. • 10/04/2024 01:15:00 PM
- Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend] • Edgar (US Regulatory) • 09/24/2024 08:03:22 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/24/2024 08:01:21 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/24/2024 08:01:08 PM
- Capricor Therapeutics Announces Intent to File Biologics License Application for Full Approval of Deramiocel for the Treatment of Duchenne Muscular Dystrophy Cardiomyopathy • GlobeNewswire Inc. • 09/24/2024 12:00:00 PM
- Capricor Therapeutics to Provide Duchenne Muscular Dystrophy Program Update on September 24, 2024 • GlobeNewswire Inc. • 09/23/2024 01:25:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/17/2024 01:15:10 PM
Avant Technologies and Ainnova Tech Form Joint Venture to Advance Early Disease Detection Using Artificial Intelligence • AVAI • Nov 12, 2024 9:00 AM
Swifty Global Announces Launch of Swifty Sports IE, Expanding Sports Betting and Casino Services in the Irish Market • DRCR • Nov 12, 2024 9:00 AM
Oohvie App Update Enhances Women's Health with Telemedicine and Online Scheduling • HLYK • Nov 11, 2024 8:00 AM
SANUWAVE Announces Record Quarterly Revenues: Q3 FY2024 Financial Results • SNWV • Nov 8, 2024 7:07 AM
DBG Pays Off $1.3 Million in Convertible Notes, which Retires All of the Company's Convertible Notes • DBGI • Nov 7, 2024 2:16 PM
SMX and FinGo Enter Into Collaboration Mandate to Develop a Joint 'Physical to Digital' Platform Service • SMX • Nov 7, 2024 8:48 AM